<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763473</url>
  </required_header>
  <id_info>
    <org_study_id>H-2020-248</org_study_id>
    <nct_id>NCT04763473</nct_id>
  </id_info>
  <brief_title>AVocAdo Extract to Improve gLycemia in Individuals With Obesity (AVAIL)</brief_title>
  <official_title>AVocAdo Extract to Improve gLycemia in Individuals With Obesity (AVAIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Adelaide</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Isagenix International LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Commonwealth Scientific and Industrial Research Organisation, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prolongevity Technologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Adelaide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This two-arm, double blind, randomized clinical trial will compare the effect of an avocado&#xD;
      extract, compared to placebo, on cardiometabolic outcomes in adults with obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty eligible participants will be stratified by sex and randomly assigned to placebo or&#xD;
      avocado extract supplementation group for 12 weeks. Metabolic testing will be performed at&#xD;
      baseline, and at the end of the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in glucose area under the curve (AUC) in response to 75 g oral glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in fasting insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial insulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in insulin AUC in response to 75g oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic model assessment of insulin resistance (HOMA-IR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c (HbA1c)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist and hip circumference</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in waist hip circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in body composition assessed by dual-energy X-ray absorptiometry (DEXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in blood C-reactive protein</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will consume 10 grams of corn meal daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avocado extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Avocado extract</intervention_name>
    <description>Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.</description>
    <arm_group_label>Avocado extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will consume 10 grams of corn meal daily for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women 25 - 65 years old&#xD;
&#xD;
          -  Waist circumference (&gt;94cm in men and &gt;80cm in women)&#xD;
&#xD;
          -  BMI 30 - 40 kg/m2&#xD;
&#xD;
          -  Willingness to provide written informed consent and willingness to participate and&#xD;
             comply with the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women planning pregnancy during the course of the study or 3 months after completion&#xD;
             of the study, or who are lactating&#xD;
&#xD;
          -  Individuals diagnosed with type 1 or type 2 diabetes mellitus, liver or kidney&#xD;
             diseases, neoplastic disease in the previous 3 years, chronic gastrointestinal&#xD;
             disorders (including inflammatory bowel disease and celiac), cardiovascular event in&#xD;
             the previous 6 months, or any other condition deemed unstable&#xD;
&#xD;
          -  Biochemical abnormalities or evidence at screening of disease including elevated liver&#xD;
             enzymes ALT and/or AST &gt;3 times normal range limit&#xD;
&#xD;
          -  Not weight-stable (&lt; 5 % fluctuation in their body weight for past 6-months at study&#xD;
             entry).&#xD;
&#xD;
          -  Current or recent (within 12 months) treatment with medication used to lower blood&#xD;
             glucose or antidiabetic medications (metformin, sulfonylureas, glucagon-like peptide-1&#xD;
             (GLP-1) analogues [i.e. exenatide], thiazolidinediones or DPP-IV inhibitors [i.e.&#xD;
             'gliptins']), medications affecting weight, appetite or gut motility (i.e.&#xD;
             domperidone, cisapride, orlistat, phentermine, topiramate). Participants who are&#xD;
             taking stable doses (i.e. &gt; 12 months) of androgenic medications (i.e. testosterone),&#xD;
             thyroxine, corticosteroids, anti-depressants (selective serotonin reuptake&#xD;
             inhibitors), anti-hypertensives (ace-inhibitors, calcium channel blockers,&#xD;
             beta-blockers, diuretics) and lipid lowering medications (statins, fibrates) will not&#xD;
             be excluded.&#xD;
&#xD;
          -  Participants who have had bariatric surgery&#xD;
&#xD;
          -  Participants with conditions that may interfere with the ability to understand the&#xD;
             requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonie Heilbronn</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Adelaide</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leonie Heilbronn</last_name>
    <phone>+61881284838</phone>
    <email>leonie.heilbronn@adelaide.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Adelaide</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonie Heilbronn, PhD</last_name>
      <phone>+61 08 81284838</phone>
      <email>leonie.heilbronn@adelaide.edu.au</email>
    </contact>
    <investigator>
      <last_name>Bo Liu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Adelaide</investigator_affiliation>
    <investigator_full_name>A/Prof Leonie Heilbronn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Avocado extract</keyword>
  <keyword>Cardiometabolic health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

